Panel discussion

Incyte Biosciences International Sàrl

Date:April 22, 2024
Room:Marriott Hotel

Panel title

Are Current Incentives to Promote Drug Innovation in Healthcare Sustainable?

Panel summary

In the context of rising expectations and heightened budgetary pressures, it is crucial to delve into the significance of implementing the right incentives to foster continued research, development, and commercialization for innovative medicines. With speakers from different parts of the healthcare sector, this panel will discuss the tensions in the system and the role of all stakeholders in addressing these and making innovation a reality for patients.

Speaker information


Christophe Hilbert, Director, European Reimbursement and Access, Incyte Biosciences International Sàrl


Hervé Lamarque, Division Vice President, Head of Value Access Pricing & Business Development Europe, Incyte Biosciences International Sàrl
Rosmarie Pfau, Founder & President,
Elisabeth Roider, MD, PhD, MBA, Physician scientist, Universitätsspital Basel
Dr. med. et lic. iur. HSG Andreas Wildi, attorney-at-law, Partner, Walder Wyss AG

Company profile

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development & commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients & a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

Further information

Follow us